Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S293000
Reexamination Certificate
active
07977347
ABSTRACT:
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
REFERENCES:
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 6414148 (2002-07-01), Thomas et al.
patent: 6900221 (2008-05-01), Norris et al.
patent: 2004/0265228 (2004-12-01), Levitzki et al.
patent: 2006/0025430 (2006-02-01), Mishani et al.
patent: 2006/0111375 (2006-05-01), Shimizu et al.
patent: 2008/0139590 (2008-06-01), Qia et al.
patent: 2008/0194578 (2008-08-01), Qian et al.
patent: 2008/0221132 (2008-09-01), Cai et al.
patent: 0 566 226 (1993-10-01), None
patent: WO 98/013354 (1998-04-01), None
patent: 00/47212 (2000-08-01), None
patent: 03/055866 (2003-07-01), None
patent: WO 2004/105765 (2004-12-01), None
patent: 2005/030757 (2005-04-01), None
patent: 2005/097137 (2005-10-01), None
patent: WO 2005/097134 (2005-10-01), None
patent: 2006/082428 (2006-08-01), None
patent: 2006113498 (2006-10-01), None
Patani, et al. Chem. Rev., 96, 1996, 3147-3176.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.
Hackam, et al. JAMA, 296(14), 2006, 1731-1732.
Hennequin, et al., “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,” J. Med. Chem., 30: 5369-5389 (1999).
Cai Xiong
Qian Changgeng
Curis, Inc.
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Harlan Edgar W.
Willis Douglas M
LandOfFree
Quinazoline based EGFR inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline based EGFR inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline based EGFR inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638332